دورية أكاديمية
أعرض في EDS

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

التفاصيل البيبلوغرافية
العنوان: CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
المؤلفون: Cen HJ; School of Pharmaceutical Sciences, Sun Yat-sen University, China., Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ
المصدر: British journal of clinical pharmacology [Br J Clin Pharmacol] 2010 Aug; Vol. 70 (2), pp. 234-40.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Wiley-Blackwell
Original Publication: London, Macmillan Journals Ltd.
مواضيع طبية MeSH: Genotype* , Heart Valve Prosthesis Implantation*, Anticoagulants/*administration & dosage , Cytochrome P-450 Enzyme System/*genetics , Warfarin/*administration & dosage, Adult ; Alleles ; Aryl Hydrocarbon Hydroxylases/genetics ; Asian People/genetics ; China ; Cytochrome P-450 CYP2C9 ; Cytochrome P450 Family 4 ; Dose-Response Relationship, Drug ; Female ; Gene Frequency ; Heart Valves/surgery ; Humans ; Male ; Middle Aged ; Mixed Function Oxygenases/genetics ; Polymorphism, Genetic ; Polymorphism, Restriction Fragment Length ; Sequence Analysis, DNA ; Vitamin K Epoxide Reductases
مستخلص: WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Genetic polymorphisms of VKORC1 and CYP2C9 are known to influence warfarin dosage. * Recent studies among Caucasians showed that polymorphisms of CYP4F2 also play a role in warfarin pharmacogenetics. * The contribution of CYP4F2 variants to the variability inwarfarin dose requirement in Chinese subjects remains to be investigated. WHAT THIS STUDY ADDS * This research was to study the effect of CYP4F2 variants on warfarin requirements in the Han Chinese population. * This study developed a multiple regression model including CYP2C9, VKORC1 3673G>A, CYP4F2 genotypes and age, weight, combination use of amiodarone which could explain 56.1% of the individual variability in warfarin dose CYP4F2 could explain 4% of the variance in warfarin dose. * We found that one novel genotypic polymorphism 5417G>T for Asp36Tyr, which was identified as an important marker of warfarin resistance, was absent in the Han Chinese population in our study. AIMS The objective of this study was to assess the effect of the CYP4F2 on the daily stable warfarin dose requirement in Han Chinese patients with mechanical heart valve replacement (MHVR). METHODS From March 2007 to November 2008, 222 Han Chinese MHVR patients were recruited in our study. VKORC1 3673G>A, 5417G>T, CYP2C9*3 and CYP4F2 rs2108622 were genotyped by using the polymerase chain reaction restriction fragment length polymorphism method (PCR-RFLP). Polymorphisms of VKORC1 9041G>A were detected by direct sequencing. Multiple linear regression analysis was used to investigate the contribution of CYP4F2. RESULTS The CYP4F2 rs2108622 CT/TT group took a significantly higher stable warfarin dose (3.2 mg day(-1)) than the CC group (2.9 mg day(-1), 95% CI 0.2, 1.0, P= 0.033). The multiple linear regression model included VKORC1 3673G>A, CYP2C9, CYP4F2 genotypes and clinical characteristics. The model could explain 56.1% of the variance in stable warfarin dose in Han Chinese patients with MHVR. CYP4F2 contributed about 4% to the variance in the warfarin dose. There was no variation in the SNPs of VKORC1 5417G>T. CONCLUSION CYP4F2 is a minor significant factor of individual variability in the stable warfarin dose in Han Chinese patients with MHVR. The effect of CYP2C9 and VKORC1 genotypes on variability in the stable warfarin dose had also been confirmed.
References: Arch Intern Med. 2005 May 23;165(10):1095-106. (PMID: 15911722)
Clin Pharmacol Ther. 2008 Dec;84(6):722-8. (PMID: 18754001)
Clin Pharmacol Ther. 2006 Aug;80(2):169-78. (PMID: 16890578)
Clin Med Res. 2007 Mar;5(1):8-16. (PMID: 17456829)
J Pharmacol Exp Ther. 1998 Jun;285(3):1327-36. (PMID: 9618440)
Blood. 2008 Aug 15;112(4):1022-7. (PMID: 18535201)
Mol Pharmacol. 2009 Jun;75(6):1337-46. (PMID: 19297519)
Blood. 2007 Mar 15;109(6):2477-80. (PMID: 17110455)
Clin Med Res. 2005 Aug;3(3):137-45. (PMID: 16160068)
Pharmacogenomics. 2007 Nov;8(11):1545-50. (PMID: 18034619)
Biochem Biophys Res Commun. 1999 Jan 27;254(3):628-31. (PMID: 9920790)
PLoS Genet. 2009 Mar;5(3):e1000433. (PMID: 19300499)
Clin Pharmacol Ther. 2006 Apr;79(4):291-302. (PMID: 16580898)
Nucleic Acids Res. 1976 Sep;3(9):2303-8. (PMID: 987581)
Pharmacogenetics. 1996 Aug;6(4):341-9. (PMID: 8873220)
Clin Appl Thromb Hemost. 2006 Apr;12(2):219-22. (PMID: 16708125)
Thromb Haemost. 2004 Jan;91(1):87-94. (PMID: 14691573)
Pharmacogenetics. 2004 Aug;14(8):539-47. (PMID: 15284536)
Blood. 2008 Apr 1;111(7):3903-4. (PMID: 18362220)
Clin Chim Acta. 2008 Oct;396(1-2):76-9. (PMID: 18680736)
Am J Hum Genet. 2008 Feb;82(2):495-500. (PMID: 18252229)
Clin Pharmacol Ther. 2008 Mar;83(3):460-70. (PMID: 17851566)
Hum Mol Genet. 2005 Jul 1;14(13):1745-51. (PMID: 15888487)
Basic Clin Pharmacol Toxicol. 2006 Jun;98(6):611-3. (PMID: 16700826)
Eur J Clin Pharmacol. 2007 Dec;63(12):1135-41. (PMID: 17899045)
Nature. 2003 Dec 18;426(6968):789-96. (PMID: 14685227)
Blood. 2008 Apr 15;111(8):4106-12. (PMID: 18250228)
J Biol Chem. 2002 Jul 12;277(28):25290-6. (PMID: 11997390)
Pharmacogenomics. 2009 Feb;10(2):261-6. (PMID: 19207028)
المشرفين على المادة: 0 (Anticoagulants)
5Q7ZVV76EI (Warfarin)
9035-51-2 (Cytochrome P-450 Enzyme System)
EC 1.- (Mixed Function Oxygenases)
EC 1.14.13.- (CYP2C9 protein, human)
EC 1.14.13.- (Cytochrome P-450 CYP2C9)
EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
EC 1.14.14.1 (Cytochrome P450 Family 4)
EC 1.14.14.78 (CYP4F2 protein, human)
EC 1.17.4.4 (VKORC1 protein, human)
EC 1.17.4.4 (Vitamin K Epoxide Reductases)
تواريخ الأحداث: Date Created: 20100727 Date Completed: 20110105 Latest Revision: 20221207
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC2911553
DOI: 10.1111/j.1365-2125.2010.03698.x
PMID: 20653676
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2125
DOI:10.1111/j.1365-2125.2010.03698.x